Skip to main content

Table 3 Transplant outcomes for patients that underwent allogeneic stem cell transplantation in the retrospective and prospective study

From: Haploidentical allograft is superior to matched sibling donor allograft in eradicating pre-transplantation minimal residual disease of AML patients as determined by multiparameter flow cytometry: a retrospective and prospective analysis

  

Neutrophil engraftment

Platelet engraftment

Grades 2–4 acute GVHD

Chronic GVHD at 4 years

Relapse at 4 years

NRM at 4 years

LFS at 4 years

OS at 4 years

Retrospective study group (n = 339)

MSDT (n = 99)

MRDneg (group A)

98% (95% CI, 96–100%)

98% (95% CI, 94–100%)

9% (95% CI, 3 to 15%) ‡, ##

58% (95% CI, 45 to 71%)

11% (95% CI, 4 to 18%)

16% (95% CI, 7 to 25%)

73% (95% CI, 63 to 83%)

76% (95% CI, 66 to 86%)

MRDpos (group B)

93% (95% CI, 79–100%) £

93% (95% CI, 79–100%)

7% (95% CI, 0 to 21%) †, #

66% (95% CI, 35 to 97%)

60% (95% CI, 22 to 98%)

7% (95% CI, 0 to 21%)

33% (95% CI, 2 to 64%)

33% (95% CI, 2 to 64%)

Haplo-SCT (n = 240)

MRDneg (group C)

99% (95% CI, 99–100%)

99% (95% CI, 97–100%)

36% (95% CI, 29 to 43%)

48% (95% CI, 40 to 56%)

15% (95% CI, 10 to 20%)

14% (95% CI, 9 to 19%)

71% (95% CI, 65 to 77%)

75% (95% CI, 69 to 81%)

MRDpos (group D)

98% (95% CI, 96–100%)

97% (95% CI, 93–100%)

43% (95% CI, 29 to 57%)

70% (95% CI, 56 to 84%) *

19% (95% CI, 5 to 33%)

8% (95% CI, 1 to 15%)

73% (95% CI, 58 to 88%)

75% (95% CI, 60 to 90%)

Prospective study group (n = 340) a

MSDT (n = 82)

MRDneg (group E)

98% (95% CI, 95–100%)

98% (95% CI, 94–100%)

10% (95% CI, 2 to 17%) $, $$

56% (95% CI, 39 to 72%)

7% (95% CI, 0 to 13%)

5% (95% CI, 0 to 11%)

88% (95% CI, 79 to 97%)

94% (95% CI, 87 to 100%)

MRDpos (group F)

95% (95% CI, 85–100%) ££

95% (95% CI, 85–100%)

5% (95% CI, 0 to 15%) ††, ‡‡

41% (95% CI, 20 to 62%)

36% (95% CI, 14 to 58%)

16% (95% CI, 0 to 33%)

48% (95% CI, 25 to 71%)

64% (95% CI, 42 to 86%)

Haplo-SCT (n = 258)

MRDneg (group G)

99% (95% CI, 99–100%)

99% (95% CI, 99–100%)

28% (95% CI, 21 to 35%)

40% (95% CI, 31 to 49%)

7% (95% CI, 3 to 11%)

18% (95% CI, 12 to 24%)

75% (95% CI, 69 to 81%)

78% (95% CI, 72 to 84%)

MRDpos (group H)

97% (95% CI, 91–100%)

98% (95% CI, 94–100%)

32% (95% CI, 20 to 44%)

73% (95% CI, 52 to 94%) **

13% (95% CI, 4 to 22%)

7% (95% CI, 0 to 14%)

80% (95% CI, 69 to 91%)

83% (95% CI, 73 to 93%)

  1. The differences in any of the transplant outcomes between the four groups were analyzed with a log-rank test
  2. Abbreviations: GVHD graft-versus-host disease, NRM non-relapse mortality, LFS leukemia-free survival, OS overall survival, MRD minimal residual disease, MSDT human leukocyte antigen-matched sibling donor transplantation, MRDpos MRD positive, MRDneg MRD negative, Haplo-SCT haploidentical stem cell transplantation
  3. £ P < 0.01 compared with group D
  4. ££ P < 0.05 compared with group D
  5. ‡ P < 0.05 compared with group C
  6. ## P < 0.01 compared with group D
  7. † P < 0.05 compared with group C
  8. # P < 0.01 compared with group D
  9. *P = 0.980 compared with group B
  10. $ P < 0.01 compared with group G
  11. $$ P < 0.01 compared with group H
  12. †† P < 0.05 compared with group G
  13. ‡‡ P < 0.05 compared with group H
  14. **P = 0.223 compared with group F
  15. aIndicates the transplant outcomes of patients in the prospective study are listed as chronic GVHD, relapse, NRM, LFS and OS at 2 years
Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us